Published in Am J Physiol Heart Circ Physiol on February 12, 2010
Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov (2012) 4.30
Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol (2010) 2.35
Cardiac Fibrosis: The Fibroblast Awakens. Circ Res (2016) 1.21
Importance of myocyte-nonmyocyte interactions in cardiac development and disease. Circ Res (2012) 1.07
Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling. Int J Inflam (2011) 1.02
High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. Nat Commun (2015) 1.01
Good and bad sides of TGFβ-signaling in myocardial infarction. Front Physiol (2015) 0.88
Antifibrotic therapies to control cardiac fibrosis. Biomater Res (2016) 0.86
Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in Chagas disease. PLoS Negl Trop Dis (2012) 0.86
Transforming growth factor β receptor 1 is a new candidate prognostic biomarker after acute myocardial infarction. BMC Med Genomics (2011) 0.84
Targeting the transforming growth factor (TGF)-β cascade in the remodeling heart: benefits and perils. J Mol Cell Cardiol (2014) 0.81
3',4'-Dihydroxyflavonol antioxidant attenuates diastolic dysfunction and cardiac remodeling in streptozotocin-induced diabetic m(Ren2)27 rats. PLoS One (2011) 0.80
Pharmacological inhibition of TGFβ receptor improves Nkx2.5 cardiomyoblast-mediated regeneration. Cardiovasc Res (2014) 0.79
Novel strategies for the treatment of heart failure. Rambam Maimonides Med J (2012) 0.77
The TGF-β pathway mediates doxorubicin effects on cardiac endothelial cells. J Mol Cell Cardiol (2015) 0.76
Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-β. Lab Invest (2016) 0.75
Transforming growth factor β and its role in heart disease. Exp Ther Med (2017) 0.75
Myocardial fibrosis in congenital and pediatric heart disease. Exp Ther Med (2017) 0.75
Transforming growth factor β: A potential biomarker and therapeutic target of ventricular remodeling. Oncotarget (2017) 0.75
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med (2015) 6.03
Genomic analyses identify distinct patterns of selection in domesticated pigs and Tibetan wild boars. Nat Genet (2013) 3.41
Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus. PLoS Pathog (2011) 2.95
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res (2006) 2.92
The (Pro)renin receptor: site-specific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension (2009) 2.47
Demographics and concomitant disorders in heart failure. Lancet (2003) 2.30
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol (2005) 1.96
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ (2013) 1.86
Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. Mol Endocrinol (2008) 1.85
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Disruption of nesprin-1 produces an Emery Dreifuss muscular dystrophy-like phenotype in mice. Hum Mol Genet (2008) 1.83
Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart. Eur J Heart Fail (2012) 1.82
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A (2007) 1.82
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther (2005) 1.81
Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest (2002) 1.80
Rapid multislice imaging of hyperpolarized 13C pyruvate and bicarbonate in the heart. Magn Reson Med (2010) 1.80
Outcomes of congenital diaphragmatic hernia in the modern era of management. J Pediatr (2013) 1.80
Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC. Electrophoresis (2011) 1.75
Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem (2006) 1.72
Plasmin is not protective in experimental renal interstitial fibrosis. Kidney Int (2004) 1.71
Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol (2005) 1.67
Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet (2009) 1.66
Mast cell infiltration and chemokine expression in progressive renal disease. Kidney Int (2003) 1.61
Urotensin II: a new player in vascular and myocardial disease? Clin Sci (Lond) (2003) 1.59
Structure and interactions of plant cell-wall polysaccharides by two- and three-dimensional magic-angle-spinning solid-state NMR. Biochemistry (2011) 1.57
n-3 Polyunsaturated fatty acids alter expression of fibrotic and hypertrophic genes in a dog model of atrial cardiomyopathy. Heart Rhythm (2009) 1.54
An acute experimental model demonstrating 2 different forms of sustained atrial tachyarrhythmias. Circ Arrhythm Electrophysiol (2009) 1.54
ECM1 controls T(H)2 cell egress from lymph nodes through re-expression of S1P(1). Nat Immunol (2011) 1.54
Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther (2005) 1.53
Structural, electrical, and optical properties of Ti-doped ZnO films fabricated by atomic layer deposition. Nanoscale Res Lett (2013) 1.50
Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Renal Physiol (2005) 1.48
Nesprin-1 mutations in human and murine cardiomyopathy. J Mol Cell Cardiol (2009) 1.48
Liver X receptor alpha is a transcriptional repressor of the uncoupling protein 1 gene and the brown fat phenotype. Mol Cell Biol (2008) 1.47
Direct repair of displaced anterior arch fracture of the atlas under microendoscopy: experience with seven patients. Eur Spine J (2011) 1.46
Liver X receptors regulate adrenal cholesterol balance. J Clin Invest (2006) 1.45
Differential responses of infectious diseases to economic growth in China. Int J Infect Dis (2011) 1.45
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
Membrane protein structure and dynamics from NMR spectroscopy. Annu Rev Phys Chem (2011) 1.43
Anatomy and physiology of the right interganglionic nerve: implications for the pathophysiology of inappropriate sinus tachycardia. J Cardiovasc Electrophysiol (2008) 1.42
Retracted Open reduction and closed reduction internal fixation in treatment of femoral neck fractures: a meta-analysis. BMC Musculoskelet Disord (2014) 1.42
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin Immunol (2008) 1.42
SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J Biol Chem (2009) 1.39
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Total phenolic contents and antioxidant capacities of selected chinese medicinal plants. Int J Mol Sci (2010) 1.35
Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J Biol Chem (2008) 1.29
Full-length genome sequences of two SARS-like coronaviruses in horseshoe bats and genetic variation analysis. J Gen Virol (2006) 1.28
Visible-light photoredox catalysis in flow. Angew Chem Int Ed Engl (2012) 1.28
Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res (2006) 1.28
Comparison on genomic predictions using three GBLUP methods and two single-step blending methods in the Nordic Holstein population. Genet Sel Evol (2012) 1.27
eNOS deficiency predisposes podocytes to injury in diabetes. J Am Soc Nephrol (2012) 1.26
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol (2011) 1.24
Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertens (2007) 1.23
Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J (2010) 1.22
Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J Am Soc Nephrol (2009) 1.22
Cardiorenal syndrome: the emerging role of protein-bound uremic toxins. Circ Res (2012) 1.21
Ground tit genome reveals avian adaptation to living at high altitudes in the Tibetan plateau. Nat Commun (2013) 1.20
Optical and microstructural properties of ZnO/TiO2 nanolaminates prepared by atomic layer deposition. Nanoscale Res Lett (2013) 1.19
Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS One (2011) 1.18
Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res (2003) 1.18
The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest (2012) 1.18
Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol (2004) 1.18
Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician (2011) 1.17
Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney Int (2011) 1.17
Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism. Am J Pathol (2011) 1.17
Cyanomethanaminium tetra-fluoro-borate. Acta Crystallogr Sect E Struct Rep Online (2010) 1.17
Polycyclic aromatic hydrocarbons (PAHs) in urban soils of the megacity Shanghai: occurrence, source apportionment and potential human health risk. Sci Total Environ (2013) 1.17
Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail (2009) 1.16
Strong, conductive, lightweight, neat graphene aerogel fibers with aligned pores. ACS Nano (2012) 1.16
COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci (2003) 1.16
Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes (2003) 1.15
Both miR-17-5p and miR-20a alleviate suppressive potential of myeloid-derived suppressor cells by modulating STAT3 expression. J Immunol (2011) 1.15
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.15
High-efficiency polymer solar cells enhanced by solvent treatment. Adv Mater (2013) 1.14
Characterizing myocardial edema and hemorrhage using quantitative T2 and T2* mapping at multiple time intervals post ST-segment elevation myocardial infarction. Circ Cardiovasc Imaging (2012) 1.13
Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS One (2010) 1.13